Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection

AIDS

Volumn 24, Issue 6, 2010, Pages 875-884

  Planque, Stephanie ^a   Salas, Maria ^b   Mitsuda, Yukie ^a   Sienczyk, Marcin ^a   Escobar, Miguel A ^a   Mooney, Jason P ^b   Morris, Mary Kate ^b   Nishiyama, Yasuhiro ^a   Ghosh, Dipanjan ^a   Kumar, Amit ^c   Gao, Feng ^c   Hanson, Carl V ^b   Paul, Sudhir ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b VIRAL AND RICKETTSIAL DISEASE LABORATORY   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

B cell superantigen; CD4 binding site; HIV diversity; HIV vaccine; Neutralizing antibodies

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; IMMUNOGLOBULIN A;

ADAPTIVE IMMUNITY; ADSORPTION CHROMATOGRAPHY; ADULT; AFFINITY CHROMATOGRAPHY; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; BINDING SITE; CASE REPORT; ENZYME LINKED IMMUNOSORBENT ASSAY; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOADSORPTION; MUTATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SURVIVOR; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS STRAIN;

AIDS VACCINES; ANTIGENS, CD4; BINDING SITES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; NEUTRALIZATION TESTS; SURVIVORS;

EID: 77949558491     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283376e88     Document Type: Article

References (49)

1. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008; 372:1894-1905.
2. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194:1661-1671.
3. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2220.
4. Roben P, Moore JP, Thali M, Sodroski J, Barbas CF 3rd, Burton DR. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 1994; 68:4821-4828.
5. Conley AJ, Gorny MK, Kessler JA 2nd, Boots LJ, Ossorio-Castro M, Koenig S, et al. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J Virol 1994; 68:6994-7000.
6. Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, Lloyd KO, et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 2002; 76:7293-7305.
7. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993; 67:6642-6647.
8. Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, Kayman SC. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J Virol 2004; 78:5205-5215.
9. Gorny MK, Stamatatos L, Volsky B, Revesz K, Williams C, Wang XH, et al. Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J Virol 2005; 79:5232-5237.
10. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326:285-289.
11. Matyas GR, Wieczorek L, Beck Z, Ochsenbauer-Jambor C, Kappes JC, Michael NL, et al. Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes. AIDS 2009; 23:2069-2077.
12. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, et al. Comprehensive cross-clade neutralization analysis of a panel of antihuman immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004; 78:13232-13252.
13. Chuenchitra T, Wasi C, Louisirirojchanakul S, Nitayaphan S, Sutthent R, Cox JH, et al. Longitudinal study of humoral immune responses in HIV type 1 subtype CRF01-AE (E)-infected Thai patients with different rates of disease progression. AIDS Res Hum Retroviruses 2003; 19:293-305.
14. Braibant M, Brunet S, Costagliola D, Rouzioux C, Agut H, Katinger H, et al. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term nonprogressors: prevalence and association with neutralizing activity. AIDS 2006; 20:1923-1930.
15. Li Y, Migueles SA, Welcher B, Svehla K, Phogat A, Louder MK, et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 2007; 13:1032-1034.
16. Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, Xiang SH, et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007; 445:732-737.
17. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glyco-protein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393:648-659.
18. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, Stanfield RL, et al. Structure of a V3-containing HIV-1 gp120 core. Science 2005; 310:1025-1028.
19. Olshevsky U, Helseth E, Furman C, Li J, Haseltine W, Sodroski J. Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J Virol 1990; 64:5701-5707.
20. Pantophlet R, Ollmann Saphire E, Poignard P, Parren PW, Wilson IA, Burton DR. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol 2003; 77:642-658.
21. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S, et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002; 420:678-682.
22. Herrera C, Spenlehauer C, Fung MS, Burton DR, Beddows S, Moore JP. Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site. J Virol 2003; 77:1084-1091.
23. Goodglick L, Zevit N, Neshat MS, Braun J. Mapping the Ig superantigen-binding site of HIV-1 gp120. J Immunol 1995; 155:5151-5159.
24. Karray S, Zouali M. Identification of the B cell superantigen-binding site of HIV-1 gp120. Proc Natl Acad Sci USA 1997; 94:1356-1360.
25. Berberian L, Goodglick L, Kipps TJ, Braun J. Immunoglobulin VH3 gene products: natural ligands for HIV gp120. Science 1993; 261:1588-1591.
26. Paul S, Karle S, Planque S, Taguchi H, Salas M, Nishiyama Y, et al. Naturally occurring proteolytic antibodies: selective immunoglobulin M-catalyzed hydrolysis of HIV gp120. J Biol Chem 2004; 279:39611-39619.
27. Planque S, Mitsuda Y, Taguchi H, Salas M, Morris MK, Nishiya-ma Y, et al. Characterization of gp120 hydrolysis by IgA antibodies from humans without HIV Infection. AIDS Res Hum Retroviruses 2007; 23:1541-1554.
28. Townsley-Fuchs J, Kam L, Fairhurst R, Gange SJ, Goodglick L, Giorgi JV, et al. Human immunodeficiency virus-1 (HIV-1) gp120 superantigen-binding serum antibodies. A host factor in homosexual HIV-1 transmission. J Clin Invest 1996; 98: 1794-1801.
29. Karray S, Juompan L, Maroun RC, Isenberg D, Silverman GJ, Zouali M. Structural basis of the gp120 superantigen-binding site on human immunoglobulins. J Immunol 1998; 161:6681-6688.
30. Neshat MN, Goodglick L, Lim K, Braun J. Mapping the B cell superantigen binding site for HIV-1 gp120 on a V(H)3 Ig. Int Immunol 2000; 12:305-312.
31. Juompan L, Lambin P, Zouali M. Selective deficit in antibodies specific for the superantigen binding site of gp120 in HIV infection. FASEB J 1998; 12:1473-1480.
32. Goodyear CS, Silverman GJ. Death by a B cell superantigen: in vivo VH-targeted apoptotic supraclonal B cell deletion by a Staphylococcal toxin. J Exp Med 2003; 197:1125-1139.
33. Jendholm J, Samuelsson M, Cardell LO, Forsgren A, Riesbeck K. Moraxella catarrhalis-dependent tonsillar B cell activation does not lead to apoptosis but to vigorous proliferation resulting in nonspecific IgM production. J Leukoc Biol 2008; 83: 1370-1378.
34. Mitsuda Y, Planque S, Hara M, Kyle R, Taguchi H, Nishiyama Y, Paul S. Naturally occurring catalytic antibodies: evidence for preferred development of the catalytic function in IgA class antibodies. Mol Biotechnol 2007; 36:113-122.
35. Karle S, Nishiyama Y, Taguchi H, Zhou YX, Luo J, Planque S, et al. Carrier-dependent specificity of antibodies to a conserved peptide determinant of gp120. Vaccine 2003; 21:1213-1218.
36. Paul S, Planque S, Zhou YX, Taguchi H, Bhatia G, Karle S, et al. Specific HIV gp120-cleaving antibodies induced by covalently reactive analog of gp120. J Biol Chem 2003; 278:20429-20435.
37. Planque S, Taguchi H, Burr G, Bhatia G, Karle S, Zhou YX, et al. Broadly distributed chemical reactivity of natural antibodies expressed in coordination with specific antigen binding activity. J Biol Chem 2003; 278:20436-20443.
38. Karle S, Planque S, Nishiyama Y, Taguchi H, Zhou YX, Salas M, et al. Cross-clade HIV-1 neutralization by an antibody fragment from a lupus phage display library. AIDS 2004; 18:329-331.
39. Bures R, Gaitan A, Zhu T, Graziosi C, McGrath KM, Tartaglia J, et al. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2000; 16:2019-2035.
40. Reed J, Kinzel V. A conformational switch is associated with receptor affinity in peptides derived from the CD4-binding domain of gp120 from HIV I. Biochemistry 1991; 30:4521-4528.
41. Robey FA, Harris-Kelson T, Robert-Guroff M, Batinic D, Ivanov B, Lewis MS, Roller PP. A synthetic conformational epitope from the C4 domain of HIV Gp120 that binds CD4. J Biol Chem 1996; 271:17990-17995.
42. Nishiyama Y, Mitsuda Y, Taguchi H, Planque S, Salas M, Hanson CV, Paul S. Towards covalent vaccination: improved polyclonal HIV neutralizing antibody response induced by an electrophilic gp120 V3 peptide analog. J Biol Chem 2007; 282:31250-31256.
43. Xiang SH, Doka N, Choudhary RK, Sodroski J, Robinson JE. Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. AIDS Res Hum Retroviruses 2002; 18:1207-1217.
44. Krakauer T. Stimulant-dependent modulation of cytokines and chemokines by airway epithelial cells: cross talk between pulmonary epithelial and peripheral blood mononuclear cells. Clin Diagn Lab Immunol 2002; 9:126-131.
45. Chen B, Vogan EM, Gong H, Skehel JJ, Wiley DC, Harrison SC. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 2005; 433:834-841.
46. Bermas BL, Petri M, Berzofsky JA, Waisman A, Shearer GM, Mozes E. Binding of glycoprotein 120 and peptides from the HIV-1 envelope by autoantibodies in mice with experimentally induced systemic lupus erythematosus and in patients with the disease. AIDS Res Hum Retroviruses 1994; 10:1071-1077.
47. Frazer JK, Capra JD. Immunoglobulins: structure and function. In: WE Paul, editor. Fundamental immunology. 4th ed. Philadelphia: Lippincott-Raven; 1999. pp. 37-74.
48. Nishiyama Y, Planque S, Mitsuda Y, Nitti G, Taguchi H, Jin L, et al. Toward effective HIV vaccination: induction of binary epitope reactive antibodies with broad HIV neutralizing activity. J Biol Chem 2009; 284:30627-30642.
49. Zwick MB, Bonnycastle LL, Menendez A, Irving MB, Barbas CF 3rd, Parren PW, et al. Identification and characterization of a peptide that specifically binds the human, broadly neutralizing antihuman immunodeficiency virus type 1 antibody b12. J Virol 2001; 75:6692-6699.